Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alkermes plc ALKS

Healthcare Biotechnology
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products,... see more

Recent & Breaking News (NDAQ:ALKS)

Free Research Reports on ACUR, ALKS, INWK and SCSS Issued by the Bedford Report

Marketwired April 18, 2013

Alkermes Announces Positive Results from Phase 2 Clinical Study of ALKS 5461 for Major Depressive Disorder

Business Wire April 17, 2013

Hospira, Delcath Systems, Valeant Pharma, and Alkermes Under StockCall's Microscope

PR Newswire April 9, 2013

Morning Research on Valeant Pharma Intl., Hospira, Delcath Systems, and Alkermes

PR Newswire March 11, 2013

Alkermes' Corporate Presentation to be Webcast at Three Upcoming Conferences

Business Wire February 19, 2013

Free Research Report on Perusahaan Perseroan P.T. Telekomunikasi Indonesia, Alkermes plc, Mine Safety Appliances Co., Microsemi Corp. and Magellan Health Services, Inc.

Marketwired February 19, 2013

Alkermes' Corporate Presentation to be Webcast at Two Upcoming Conferences

Business Wire February 5, 2013

Alkermes plc Reports Third Quarter Fiscal 2013 Financial Results

Business Wire January 31, 2013

Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2013

Business Wire January 24, 2013

Alkermes Announces Notice of Allowance of Key U.S. Patent for Aripiprazole Lauroxil, a New Schizophrenia Drug Candidate

Business Wire January 3, 2013

Alkermes Expands CNS Pipeline and Announces Positive Results from Phase 1 Study of ALKS 3831, a Novel Antipsychotic Therapy for the Treatment of Schizophrenia

Business Wire January 3, 2013

Alkermes' Corporate Presentation to be Webcast at the 31st Annual J.P. Morgan Healthcare Conference

Business Wire January 2, 2013